| April
9, 2008
Pfizer warns of lung cancer with inhaled insulin
By Lewis Krauskopf
NEW YORK (Reuters) - Pfizer Inc and Nektar Therapeutics said on Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to stop seeking a marketing partner for the troubled product and abandon it.
Nektar shares tumbled 25 percent, while shares of MannKind Corp, which has been developing its own inhaled insulin, plummeted 58 percent. Pfizer was down slightly at $20.90.
The lung-cancer revelation dealt a final setback to Exubera, which held the promise of letting diabetics avoid needle sticks and was once projected by Pfizer to be a $2 billion-a-year blockbuster. Instead, Exubera has been a commercial flop that has sullied the inhaled insulin field.
Over the course of the clinical trials, Pfizer said six of the 4,740 Exubera-treated patients versus one of the 4,292 patients not treated with Exubera developed lung cancer. One lung cancer case was also found after Exubera reached the market.
Pfizer said on Wednesday it updated the product's labeling to include a warning with safety information about lung cancer cases found in patients who used Exubera, which U.S. regulators approved in January 2006.
The warning states all patients who developed lung cancer had a history of cigarette smoking, and that too few cases existed to determine whether the development of lung cancer is related to Exubera use.
HIGH HOPES
Despite high hopes for Exubera, it garnered few prescriptions. The medicine was dogged by concerns about lung safety and about the inconvenience of the bulky device used to administer the product.
Pfizer said in October it would stop marketing Exubera and returned rights to Nektar. Pfizer reported $12 million in Exubera sales through the first three quarters of 2007; in October it took a pretax charge of $2.8 billion related to exiting Exubera.
Since then, Exubera has not been actively marketed but existing patients were able to get prescriptions while transitioning to an alternative therapy.
The warning in the label stemmed from an ongoing review of data from the Exubera clinical trial program and post-marketing experience by Pfizer and the U.S. Food and Drug Administration, Pfizer said.
Pfizer said it will be discussing withdrawals of marketing authorizations for Exubera with regulatory agencies.
Nektar said it will cease all spending associated with its inhaled insulin programs, including a next-generation version in early clinical testing, and will not incur charges related to the event.
"The news of an increased number of lung cancer cases is disappointing given that as recent as the year-end quarterly conference call, management reiterated the high level of interest from potential partners," Pacific Growth Equities analyst Patricia Bank said in a research note.
Source: www.reuters.com
Comments:
Exubera is inhaled insulin used to treat high blood sugar in diabetic patients. Manufactured by Nektar Therapeutics and marketed by Pfizer, the FDA approved Exubera in 2006. Analysis of the clinical trial data and follow up of clinical trial participants found that 6 people in Exubera treated patients got lung cancer and only in 1 in the other group got lung cancer. In addition there was a post-marketing report of lung cancer in one Exubera-treated patient. Although currently the companies are saying that there were too few cases to determine whether the development of lung cancer is related to the use of Exubera, it is a considerable risk not to take when one is considering the ‘convenience’ of inhaled insulin versus frequent insulin injections. Despite $4 million sales in 2007 Pfizer stopped marketing Exubera, as “it did not meet customers' needs or the company's financial expectations.” Yet, according to one report, Pfizer is developing new treatments for diabetes, an area of huge unmet medical need. Last year, diabetes caused more than 284,000 deaths in the United States and it is believed that more than 6 million people in US have undiagnosed diabetes. Indeed due to the disease itself and its various complications, such as circulatory problems, nerve impairments, kidney, eye issues, etc., the pharmaceutical companies consider diabetes as a growing market.
Over a decade ago, Dr. Rath identified that the root cause of diabetes and other chronic disease is a long-term deficiency of specific cellular nutrients, which can be easily supplied and the disease progression can be halted or even reversed safely. The scientists at Dr. Rath's Research Institute have clinically proven that synergistically combined specific cellular nutrients are effective, safe, and can address the root causes of many chronic diseases, including diabetes, at the cellular level. In our clinical trials using a novel nutrient synergy method, we have observed a significant reduction in blood glucose levels, as well as reduction in complications of diabetes. You can read more about these trials and Dr. Rath's research on www.drrathresearch.org and www.cellularhealthtraining.org
|
|
